ASCO结肠癌进展专题知识.pptx

ASCO结肠癌进展南昌大学第一从属医院肿瘤科黎军和ASCO结肠癌进展专题知识第1页

分子指标预测Ⅱ期结肠癌高危复发大型研究结果Ceteximab疗效预测结肠癌辅助化疗终点Oxaliplatin相关synchronousstageIVcolorectalcancer化疗策略和方案调整其它ASCO结肠癌进展专题知识第2页

分子指标预测结肠癌高危复发及指导化疗Abr4000高通量Abr4001MSIAbr4002Abr401218qLOHASCO结肠癌进展专题知识第3页

Background:NSABPC-01/C-02、CCF、C-04、C-0648genessignificantlyassociatedwithrecurrenceriskand66genespredictiveof5FU/LVbenefit.Multivariateanalysisyielded18genes(7prognosticgenes,6predictivegenes,5referencegenes)andseparateprognosticrecurrencescore(RS)andpredictivetreatmentscore(TS)algorithms.Methods:GeneexpressionwasquantitatedbyRT-PCR.Recurrence-freeinterval(RFI),disease-freesurvival(DFS),andoverallsurvival(OS)wereanalyzedusingCoxregressionResults:IntheQUASARvalidationstudytheRSpredictedrecurrencerisk(p=0.004).TheRSalsopredictedDFS(p=0.01)andOS(p=0.04).RecurrenceriskincreasedmonotonicallywithincreasingRS.Inmultivariateanalyses,RSretainedprognosticsignificance(p=0.008)independentofmismatchrepair(MMR),Tstage,nodesexamined,grade,andlymphovascularinvasion.MMRdeficiency(p0.001)andT4stage(p=0.005).However,TSwasnotvalidatedasapredictorof5FU/LVbenefitConclusions:RSisavalidated,independentpredictorofindividualizedrecurrenceriskforstageIIcoloncancerKerretl.ASCOAbstractNo:4000ASCO结肠癌进展专题知识第4页

ToinvestigatetheincidenceofMSI-HinstageII(n=395)andstageIII(n=859)COC,itsassociationwithhistopathologicalvariablesanditsprognosticandpredictiveimpact。Patients：PETACC3-EORTC40993-SAKK60/00trialResults：MSIHwaspresentin22%(85)ofStageIIand12%(103)ofStageIIIcoloncancer.MicrosatelliteinstabilityisastrongprognosticfactorforRFSandOSwhenconsideringStageIIandStageIIICOC.SubgroupanalysissuggestsastrongereffectinStageIIthaninStageIII.ThereisnoevidenceforaneffectoftheadditionofIRI.

Tejparetl.ASCOAbstractNo:4